Dashboard/HIKAL

HIKAL

FAIRLY_VALUED

Hikal Limited

Healthcare · NSE

↓ 6.8% vs fair value

52W Low

₹146

+11.6% from low

52W High

₹457

-64.3% from high

News sentiment (2 articles)

1 bull1 neutral0 bear

Valuation Gauge

FAIRLY_VALUED-6.8% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹163

Fair Value

₹153

Fair Value Analysis

₹153

Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-cheap: P/E at 36th percentile vs sector peers.

High confidence

Cash Flow Analysis

40% weight

₹251

Balance Sheet Value

20% weight

₹123

Growth Valuation

40% weight

₹69

Price vs Market

HIKAL

Nifty 50

Shareholding Pattern

Stock Health Score

Solid Fundamentals

6.6 / 10

Profitability

6/10

ROE of 7.2% is below the Healthcare sector benchmark of 15%

Debt & Leverage

10/10

D/E ratio of 0.6x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 23.1x trades at a 86% discount to Healthcare sector median (160x) — attractively valued

Cash Flow

6/10

FCF margin of 7.8% — healthy cash generation (₹143 Cr)

Earnings Growth

3/10

5yr EPS CAGR of -17.3% — earnings are declining (sector avg growth: 18.7%)

Dividend

6/10

Dividend yield of 0.6% provides moderate shareholder returns

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

7.3%

Free cash flow / market cap

Revenue Growth (YoY)

+26.4%

Year-on-year revenue change

Profit Growth (YoY)

+551.1%

Year-on-year PAT change

Operating Cash Flow

₹280 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹6.9

P/E Ratio

23.1x

P/B Ratio

1.7x

ROE

7.2%

ROCE

11.3%

Debt / Equity

0.57x

Beta

—

Div Yield

0.6%

FCF (Cr)

₹143 Cr

Revenue (Cr)

₹1,844 Cr

EPS Growth 5Y

-17.3%

Mkt Cap (Cr)

₹1,985 Cr

52W High

₹456.8

52W Low

₹146.3

Book Value/Share

₹97.2

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹1.7K Cr	₹238 Cr	14.0%	₹-13 Cr	₹-1.06
2025-03-31	₹1.9K Cr	₹328 Cr	18.0%	₹91 Cr	₹7.36
2024-03-31	₹1.8K Cr	₹267 Cr	15.0%	₹70 Cr	₹5.64
2023-03-31	₹2.0K Cr	₹258 Cr	13.0%	₹78 Cr	₹6.36
2022-03-31	₹1.9K Cr	₹341 Cr	18.0%	₹160 Cr	₹13.02
2021-03-31	₹1.7K Cr	₹323 Cr	19.0%	₹133 Cr	₹10.80
2020-03-31	₹1.5K Cr	₹273 Cr	18.0%	₹84 Cr	₹6.85
2019-03-31	₹1.6K Cr	₹298 Cr	19.0%	₹103 Cr	₹8.36
2018-03-31	₹1.3K Cr	₹242 Cr	19.0%	₹77 Cr	₹6.26
2017-03-31	₹1.0K Cr	₹201 Cr	20.0%	₹68 Cr	₹5.49
2016-03-31	₹926 Cr	₹181 Cr	20.0%	₹41 Cr	₹3.34
2015-03-31	₹872 Cr	₹182 Cr	21.0%	₹40 Cr	₹3.28
2014-03-31	₹829 Cr	₹187 Cr	23.0%	₹64 Cr	₹5.17

Compounded Growth Rates

Sales Growth

3Y-4.8%

5Y+0.3%

10Y+6.5%

Profit Growth

3Y—

5Y—

10Y—

EPS Growth

3Y—

5Y—

10Y—

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
ALPA Alpa Laboratories Limited	₹62.1	₹198.5	+68.7%	9.4	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹670	₹1,585.8	+57.8%	103.2	7.9%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹300	₹592.5	+49.4%	7.1	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹147.6	₹281.2	+47.5%	19.5	1.9%	FAIRLY_VALUED
VIMTALABS Vimta Labs Limited	₹414.8	₹722.6	+42.6%	24.6	16.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹38.4	₹52.8	+27.2%	21	10.8%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹410	₹462.6	+11.4%	20	20.6%	FAIRLY_VALUED
KRONOX Kronox Lab Sciences Limited	₹133	₹130.7	-1.8%	16.9	24.8%	FAIRLY_VALUED